Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global In-vitro Diagnostics Enzymes Market, By Enzyme Type
7.1. In-vitro Diagnostics Enzymes Market, By Enzyme Type, 2020-2030
7.1.1. Proteases
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Polymerase & Transcriptase
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Ribonuclease
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Others
7.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global In-vitro Diagnostics Enzymes Market, By Disease Type
8.1. In-vitro Diagnostics Enzymes Market, By Disease Type, 2020-2030
8.1.1. Infectious disease
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Diabetes
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Oncology
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Cardiology
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Nephrology
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Autoimmune diseases
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global In-vitro Diagnostics Enzymes Market, By Technology Type
9.1. In-vitro Diagnostics Enzymes Market, By Technology Type, 2020-2030
9.1.1. Histology Assays
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Molecular Diagnostics
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Clinical Chemistry
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global In-vitro Diagnostics Enzymes Market, By End-use Type
10.1. In-vitro Diagnostics Enzymes Market, By End-use Type, 2020-2030
10.1.1. Pharma & Biotech
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Hospital & Diagnostic Labs
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Contract Research Organizations (CROs)
10.1.3.1. Market Revenue and Forecast (2016-2030)
10.1.4. Academic Labs
10.1.4.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global In-vitro Diagnostics Enzymes Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.1.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.1.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.1.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.1.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.1.5.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.1.5.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.1.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.1.6.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.1.6.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.2.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.2.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.2.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.2.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.2.5.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.2.5.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.2.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.2.6.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.2.6.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.2.7.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.2.7.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.2.7.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.2.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.2.8.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.2.8.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.3.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.3.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.3.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.3.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.3.5.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.3.5.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.3.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.3.6.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.3.6.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.3.7.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.3.7.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.3.7.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.3.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.3.8.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.3.8.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.4.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.4.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.4.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.4.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.4.5.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.4.5.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.4.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.4.6.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.4.6.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.4.7.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.4.7.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.4.7.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.4.8.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.4.8.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.4.8.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.5.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.5.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.5.5.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.5.5.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.5.5.4. Market Revenue and Forecast, By End-use Type (2016-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, By Enzyme Type (2016-2030)
11.5.6.2. Market Revenue and Forecast, By Disease Type (2016-2030)
11.5.6.3. Market Revenue and Forecast, By Technology Type Type (2016-2030)
11.5.6.4. Market Revenue and Forecast, By End-use Type (2016-2030)
Chapter 12. Company Profiles
12.1. Merck KGaA
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Codexis, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Amano Enzyme Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Advanced Enzymes Technologies Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Biocatalysts Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Amicogen.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Dyadic International
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. BBI Solutions
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Affymetrix
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. American Laboratories
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms